The impact of neuropsychological functioning on adherence to HAART in HIV-infected substance abuse patients

AIDS Patient Care and STDs

Volumn 23, Issue 6, 2009, Pages 455-462

  Applebaum, Allison J ^a,b   Reilly, Laura C ^a   Gonzalez, Jeffrey S ^a,d,e   Richardson, Mark A ^b,c   Leveroni, Catherine L ^a,d   Safren, Steven A ^a,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e YESHIVA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BUPRENORPHINE PLUS NALOXONE; METHADONE;

ADULT; ARTICLE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTELLIGENCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONITORING; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; PATIENT COMPLIANCE; PSYCHOLOGIC ASSESSMENT; SELF REPORT; SUBSTANCE ABUSE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG PACKAGING; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PATIENT COMPLIANCE; RISK FACTORS; RISK-TAKING; SELF DISCLOSURE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 67651174414     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2008.0181     Document Type: Article

References (74)

1. Grant I, Atkinson J, Hesselink J, et al. Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Ann Intern Med 1987; 107: 828-836.
2. Heaton R, Grant I, Butters N, et al. The HNRC 500-Neuropsychology of HIV infection at different disease stages. J Int Neuropsychol Soc 1995; 1: 231-251.
3. McArthur J, Brew B, Nath A. Neurological complications of HIV infection. Lancet Neurol 2005; 4: 543-555.
4. D'Arminio M, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004; 55: 320-328.
5. Deutsch R, Ellis R, McCutchan A, et al. AIDS-associated mild neurocognitive impairment is delayed in the era of highly active antiretroviral therapy. AIDS 2001; 15: 1898- 1899.
6. Ferrando D, Gorp W, McElhiney M. Highly active antiretroviral treatment in HIV infection: Benefits for neuropsychological function. AIDS 1998; 12: F65-G70.
7. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002; 8(Suppl 2): 115-121.
8. Tozzi V, Balestra P, Galgani S, et al. Positive and sustained effects of highly active antiretroviral therapy on HIV-1 associated neurocognitive impairment. AIDS 1999; 13: 1889- 1897.
9. Lawrence D, Major E. HIV-I and the brain: Connections between HIV-1 associated dementia, neuropathology and neuroimmuniology. Microbes Infect 2002; 4: 301-308.
10. Foley J, Ettenhofer M, Wright M, Hinkin C. Emerging issues in the neuropsychology of HIV infection. Curr HIV/AIDS Rep 2008; 5: 204-211.
11. Rausch D, Stover E. Neuroscience research in AIDS. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 231-257.
12. Norman L, Kumar A. Neuropsychological complications of HIV disease and substances of abuse. Am J Infect Dis 2006; 2: 115-124.
13. Davis P, Liddiard H, McMillan T. Neuropsychological deficits and opiate abuse. Drug Alcohol Depend 2002; 67: 105- 108.
14. Starace F, Baldassarre C, Biancolilli V, et al. Early neuropsychological impairment in HIV-seropositive intravenous drug users: Evidence from the Italian Multicentre NP HIV Study. Acta Psychiatr Scand 1998; 97: 132-138.
15. Darke S, Sims J, McDonald S, et al. Cognitive impairment among methadone maintenance patients. Addiction 2000; 95: 687-695.
16. Failde Garrido JM, Lopez Castro J, Fernandez Rodriguez V, et al. HIV-1 infection, use of drugs and neuropsychologic efficiency. An Med Interna 2005; 22: 569-574.
17. Prosser J, Cohen LJ, Steinfeld, M, et al. Neuropsychological functioning in opiate-dependent subjects receiving and following methadone maintenance treatment. Drug Alcohol Depend 2006; 84: 240-247.
18. Specka M, Finkbeiner T, Lodemann E, et al. Cognitive-motor performance of methadone-maintained patients. Eur Addict Res 2000; 6: 8-19.
19. Verdejo A, Toribio, I, Orozco C, et al. Neuropsychological functioning in methadone maintenance patients versus abstinent heroin abusers. Drug Alcohol Depend 2005; 78: 283- 288.
20. Gruber SA, Tzilos GK, Silveri MM, et al. Methadone maintenance improves cognitive performance after two months of treatment. Exp Clin Psychopharmacol 2006; 14: 157-164.
21. Albert S, Weber C, Todak G, et al. An observed performance test of medication management ability in HIV: Relation to NP status and medication adherence outcomes. AIDS Behav 1999; 3: 121-128.
22. Barclay T, Hinkin C, Castellon S, et al. Age-associated predictors ofmedication adherence in HIV-positive adults: Health beliefs, self-efficacy, and neurocognitive status.Health Psychol 2007; 26: 40-49.
23. Chesney M, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med 2000; 50: 1599-1605.
24. Hinkin C, Castellon S, Durvasula R, et al. Medication adherence among HIV positive adults: Effects of cognitive dysfunction and regimen complexity. Neurology 2002; 59: 1944-1950.
25. Hinkin C, Hardy D, Mason K, et al. Medication adherence in HIV-infected adults: Effects of patient age, cognitive status, and substance abuse. AIDS 2004; 18: S19-S25.
26. Levine A, Hinkin C, Castellon S, et al. Variations in patterns of highly active antiretroviral therapy (HAART) adherence. AIDS Behav 2005; 9: 355-362.
27. Carrieri MP, Moatti JP, Vlahov D, et al. Access to antiretroviral treatment among French HIV infected injection users: The influence of continued drug use. J Epidemiol Community Health 1999; 53: 4-8.
28. Gibson DR, McCusker J, Chesney M. Effectiveness of psychosocial interventions in preventing HIV risk behavior in injecting drug users. AIDS 1998; 12: 919-929.
29. McCusker J, Westenhouse J, Stoddard AM, et al. Use of drugs and alcohol by homosexually active men in relation to sexual practices. J Acquir Immune Defic Syndr 1990; 3: 729- 736.
30. Avants SK, Margolin A, Warburton LA, et al. Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. Am J Addict 2001; 10: 69-78.
31. Cook R, Sereika S, Hunt S, et al. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med 2001; 16: 137-139.
32. Golin C, Liu H, Hays R, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002; 17: 756-765.
33. Riera M, La Fuente, L, Castanyer B, et al. Adherence to antiretroviral therapy measured by pill count and drug serum concentrations. Variables associated with a bad adherence. Med Clin (Barc) 2002; 119: 286-292.
34. Ammassari A, Antinori A, Aloisi M, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004; 45: 394-402.
35. Haubrich R, Little S, Currier J, et al. The value of patientreported adherence to antiretroviral therapy in predicting virological and immunologic response. AIDS 1999; 13: 1099- 1107.
36. Gordillo V, del Amo J, Soriano V, et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999; 13: 1763-1769.
37. Moatti J, Carrieri M, Spire B, et al. Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. AIDS. 2000; 14: 151-155.
38. Trotta M, Ammassari A, Cozzi-Lepri A, et al. Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regiments. AIDS 2003; 17: 1099-1102.
39. Bangsberg D, Hecht F, Charlebois E, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14: 357-366.
40. Levine A, Hinkin C, Marion S, et al. Adherence to antiretroviral medications in HIV: Difference in data collected via self-report and electronic monitoring. Health Psychol 2006; 25: 329-335.
41. Wagner G. Placebo practice trials: The best predictor of adherence readiness for HAART among drug users? HIV Clin Trials 2003; 4: 269-281.
42. Deschamps, A, De Geest, S, et al. Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. AIDS Patient Care STDs 2008; 22: 735-743
43. Shacham E, Basta T, Reece M. Symptoms of psychological distress among African Americans seeking HIV-related mental health care. AIDS Patient Care STDs 2008; 22: 413- 421.
44. Cockram A, Judd F, Mijch A, Norman T. The evaluation of depression in inpatients with HIV disease. Aust N Z J Psychiatry 1999; 33: 344-335.
45. Sheehan D, Lecrubier Y, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59: 22-33.
46. Montgomery S, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389.
47. National Institute of Mental Health. CGI: Clinical Global Impression Scale - NIMH. Psychopharmacol Bull 1985; 21: 839-844.
48. American Psychiatric Association. Diagnostic And Statistical Manual Of Mental Disorders, 4th ed. Washington, D.C.: American Psychiatric Association, 1994.
49. McLellan A, Kushner H, Metzger D, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9: 199-213.
50. Wechsler D. WTAR Manual. San Antonio, TX: Harcourt Assessment, 2001.
51. Wechsler D. Wechsler Test of Adult Reading (WTAR). San Antonio, TX: Harcourt Assessment, 2001.
52. Brandt J, Benedict RHB. Hopkins Verbal Learning Test- Revised (HVLT-R). San Antonio, TX: The Psychological Corporation, 1991.
53. Carey C, Woods S, Rippeth J, et al. Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clin Neuropsychol 2004; 18: 234-248.
54. Woods S, Scott J, Dawson M, et al. Construct validity of Hopkins Verbal Learning Test-Revised component process measures in an HIV-1 sample. Arch Clin Neuropsychol 2005; 20: 1061-1071.
55. Lezac MD. Neuropsychological Assessment, 3rd ed. New York: Oxford University Press, 1995.
56. Di Sclafani V, Mackay R, Meyerhoff D, et al. Brain atrophy in HIV infection is more strongly associated with CDC clinical stages than with cognitive impairment. J Int Neuropsychol Soc 1997; 3: 276-287.
57. McCaffrey R, Krahula M, Heimberg R, et al. A comparison of the Trail Making Test, Symbol Digit Modalities Test and the Hooper Visual Organization Test in an inpatient substance abuse population. Arch Clin Neuropsychol 1988; 3: 181-187.
58. Miller K. NP assessment of substance abusers: Review and recommendations. J Subst Abuse Treat 1985; 2: 5-17.
59. Mintzer M, Stitzer M. Cognitive impairment in methadone maintenance patients. Drug Alcohol Depend. 2002; 67: 41-51.
60. Smith A. Symbol Digit Modalities Test (SDMT). San Antonio, TX: The Psychological Corporation, 1973.
61. Sacktor NC, Lyles RL, Skolasky DE, et al. Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Neurology 1999; 52: 1640.
62. Sacktor N, Skolasky RL, Rarwater PM, et al. Response to systemic HIV viral load suppression correlates with psychomotor speed performance. Neurology 2003; 61: 567-579.
63. Benton A, Hamsher K, Sivan A. Multilingual Aphasia Examination, 3rd ed. Iowa City: AJA Associates, 1983.
64. Spreen O, Strauss E. A Compendium of NP Tests: Administration, Norms, And Commentary, 2nd ed. New York: Oxford University Press, 1998.
65. Meyers JE, Meyers KR. Rey Complex Figure Test and Recognition Trial. Odessa, TX: Psychological Assessment Resources, Inc., 1995.
66. Knight J, Kaplan E, Ireland D. Survey findings of Rey-Osterrieth Complex Figure usage. In: Knight JA, ed. The Handbook of Rey-Osterrieth Complex Figure Usage: Clinical and Research Application. Lutz: PAR, 2003.
67. Brew BJ, Halman M, Catalan J, et al. Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial. PLoS Clin Trials 2007; 2: e13.
68. Clifford DB, McArthur JC, Schifitto G, et al. A randomized clinical trail of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology 2002; 59: 1568-1573.
69. Schifitto G, Zhang J, Evans SR, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology 2007; 69: 1314-1321.
70. Dolan, S, Montagno A, Wilkie S, et al. Neurocognitive function in HIV-infected patients with low weight and weight loss. J Acquir Immune Defic Syndr 2003; 34: 155-164.
71. Wagner G. Placebo practice trials: the best predictor of adherence readiness for HAART among drug users? HIV Clin Trials 2003; 4: 269-281.
72. Starace F, Baldassarre C, Biancolilli V, et al. Early neuropsychological impairment in HIV-seropositive intravenous drug users: Evidence from the Italian Multicentre Neuropsychological HIV Study. Acta Psychiatr Scand 1998; 97: 132-138.
73. Paterson D, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
74. Vriesendorop R, Cohen A, Kristanto P, et al. Adherence to HAART therapy measured by electronic monitoring in newly diagnosed HIV patients in Botswana. Eur J Clin Pharmacol 2007; 12: 1115-1121.